| Open Document File Size: 30,68 KBShare Result on Facebook
City Basel / / Company Basilea Pharmaceutica International Ltd. / Basilea Basilea Pharmaceutica Ltd. / Basilea Pharmaceutica Ltd. / Astellas Pharma Inc. / 2 Basilea Pharmaceutica Ltd. / / Country Switzerland / United States / United Kingdom / / / Event FDA Phase / Conference Call / Business Partnership / / IndustryTerm investigational product / pharmaceutical products / biopharmaceutical company developing products / / MedicalCondition invasive aspergillosis / cancer / invasive mucormycosis / bacterial infections / zygomycosis / invasive fungal disease / mucormycosis / invasive fungal infections / fungal infections / candidemia and other invasive Candida infections / / Organization European Medicines Agency / U.S. Food and Drug Administration / Advisory Committee / FDA’s Anti-Infective Drugs Advisory Committee / / Person Ronald Scott / Nils Schröder / Barbara Zink / / / Position PhD Head Public Relations & Corporate Communications / Chief Executive Officer / MBA Head Corporate Development / / Product Prescription Drug / / URL http /
SocialTag |
PRESS RELEASE Basilea announces that FDA’s Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis Basel, Switzerland, January 22, 2015